Advertisement

Comparison of Cost-Effectiveness of Oral Rapamycin Plus Bare-Metal Stents Versus First Generation of Drug-Eluting Stents (from the Randomized Oral Rapamycin in Argentina [ORAR] 3 Trial)

Published:December 16, 2013DOI:https://doi.org/10.1016/j.amjcard.2013.11.033
      The aim of this study was to compare 5-year cost-effectiveness and clinical outcomes of patients with oral rapamycin (OR) plus bare-metal stent versus the drug-eluting stent (DES) strategy. During 2006 to 2007, a total of 200 patients were randomized to OR (n = 100) and DES (n = 100). Primary end point was to compare costs of initial procedure and cost-effectiveness of both revascularization strategies. Safety was evaluated by the composite of death, myocardial infarction, and cerebrovascular accident. Efficacy was assessed by target vessel and target lesion revascularizations. The 2 groups had similar baseline demographic, clinical, and angiographic characteristics. In the DES group, paclitaxel-, zotarolimus-, and sirolimus-eluting stents were used. Five-year clinical follow-up was accomplished in 99% patients. The DES group had significantly higher procedural (p <0.001), discharge to first-year (p = 0.02), and 1- to 5-year costs (p <0.001) compared with the OR group. At 5 years, the composite end point of death, myocardial infarction, and cerebrovascular accident (12% in the OR group vs 25% in the DES group, p = 0.01) was significantly less in the OR group. Target vessel revascularization (14.5% in the OR group vs 21% in the DES group, p = 0.16) and target lesion revascularization (10% in the OR group vs 17.6% in the DES group, p = 0.05) were not significantly different. In conclusion, a strategy of OR plus bare-metal stent was cost saving than a first-generation DES.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rodríguez A.E.
        • Maree A.
        • Tarragona S.
        • Fernández- Pereira C.
        • Santaera O.
        • Rodriguez Granillo A.M.
        • Rodríguez-Granillo G.A.
        • Russo-Felssen M.
        • Kukreja N.
        • Antoniucci D.
        • Palacios I.
        • Serruys P.W.
        Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomized, controlled ORAR III (Oral Rapamycin in ARgentina) study.
        Euro Intervention. 2009; 5: 255-264
        • Rodriguez A.E.
        • Rodriguez-Granillo A.M.
        • Antoniucci D.
        • Mieres J.
        • Fernandez-Pereira C.
        • Rodriguez-Granillo G.A.
        • Santaera O.
        • Rubilar B.
        • Palacios I.F.
        • Serruys P.W.
        Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
        Catheter Cardiovasc Interv. 2012; 80: 385-394
        • Rodriguez A.E.
        • Grinfeld L.
        • Fernandez-Pereira C.
        • Mieres J.
        • Rodriguez Alemparte M.
        • Berrocal D.
        • Rodriguez-Granillo A.M.
        • Vigo C.F.
        • Russo Felsen M.
        • O’Neill W.
        • Palacios I.
        Revascularization strategies of coronary multiple vessel disease in the drug eluting stent era: one year follow-up results of the ERACI III trial.
        Euro Intervention. 2006; 2: 53-60
        • Rodriguez A.E.
        • Mieres J.
        • Fernandez-Pereira C.
        • Vigo C.F.
        • Rodriguez-Alemparte M.
        • Berrocal D.
        • Grinfeld L.
        • Palacios I.
        Coronary stent thrombosis in the current drug eluting stent era: insights from the ERACI III trial.
        J Am Coll Cardiol. 2006; 47: 205-207
        • Vranckx P.
        • Kint P.-P.
        • Morel M.-A.
        • Van Es G.-A.
        • Serruys P.W.
        • Cutlip D.
        Identifying stent thrombosis, a critical appraisal of the Academic Research Consortium (ARC) consensus definitions: a lighthouse and as a toe in the water.
        Euro Intervention. 2008; 4: C39-C44
        • Gold M.R.
        • Siegel J.E.
        • Russell L.B.
        • Weinstein M.C.
        Cost-Effectiveness in Health and Medicine.
        Oxford University Press, 1996
        • Moses J.W.
        • Leon M.B.
        • Popma J.J.
        • Fitzgerald P.J.
        • Holmes D.R.
        • O’Shaughnessy C.
        • Caputo R.P.
        • Kereiakes D.J.
        • Williams D.O.
        • Teirstein P.S.
        • Jaeger J.L.
        • Kuntz R.E.
        Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
        N Engl J Med. 2003; 349: 1315-1323
        • Stone G.W.
        • Ellis S.G.
        • Cannon L.
        • Mann J.T.
        • Greenberg J.D.
        • Spriggs D.
        • O’Shaughnessy C.D.
        • De Mario S.
        • Hall P.
        • Popma J.J.
        • Koglin J.
        • Russell M.E.
        Comparison of a polymer based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
        JAMA. 2005; 294: 1215-1223
        • Caixeta A.
        • Leon M.B.
        • Lansky A.J.
        • Nikolsky E.
        • Aoki J.
        • Moses J.W.
        • Schofer J.
        • Morice M.C.
        • Schampaert E.
        • Kirtane A.J.
        • Popma J.J.
        • Parise H.
        • Fahy M.
        • Mehran R.
        5-Year clinical outcomes after sirolimus eluting stent implantation: insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
        J Am Coll Cardiol. 2009; 54: 894-902
        • Stone G.W.
        • Ellis S.G.
        • Colombo A.
        • Grube E.
        • Popma J.J.
        • Uchida T.
        • Bleuit J.S.
        • Dawkins K.D.
        • Russell M.E.
        Long term safety and efficacy of paclitaxel eluting stents.
        J Am Coll Cardiol Intv. 2011; 4: 530-542
        • Kimura T.
        • Morimoto T.
        • Nakagawa Y.
        • Kawai K.
        • Miyazaki S.
        • Muramatsu T.
        • Shiode N.
        • Namura M.
        • Sone T.
        • Oshima S.
        • Nishi kawa H.
        • Hiasa Y.
        • Hayashi Y.
        • Nobuyoshi M.
        • Mitudo K.
        • j-Cypher Registry Investigators
        Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.
        Circulation. 2012; 125: 584-591
        • Nakazawa G.
        • Otsuka F.
        • Nakano M.
        • Vorpahl M.
        • Yazdani S.K.
        • Ladich E.
        • Kolodgie F.D.
        • Finn A.V.
        • Virmani R.
        The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents.
        J Am Coll Cardiol. 2011; 57: 1314-1322
        • Raber L.
        • Wohlwend L.
        • Wigger M.
        • Togni M.
        • Wandel S.
        • Wenaweser P.
        • Cook S.
        • Mos chovitis A.
        • Vogel R.
        • Kalesan B.
        • Seiler C.
        • Eberli F.
        • Luscher T.F.
        • Meier B.
        • Juni P.
        • Windecker S.
        Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stent: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trail.
        Circulation. 2011; 123: 2819-2828
        • Weintraub W.S.
        • Grau-Sepulveda M.V.
        • Weiss J.M.
        • O'Brien S.M.
        • Peterson E.D.
        • Kolm P.
        • Zhang Z.
        • Klein L.W.
        • Shaw R.E.
        • McKay C.
        • Ritzenthaler L.L.
        • Popma J.J.
        • Messenger J.C.
        • Shahian D.M.
        • Grover F.L.
        • Mayer J.E.
        • Shewan C.M.
        • Garratt K.N.
        • Moussa I.D.
        • Dangas G.D.
        • Edwards F.H.
        Comparative effectiveness of revascularization strategies.
        N Eng J Med. 2012; 366: 1467-1476
        • Mohr F.W.
        • Morice M.C.
        • Kappetein A.P.
        • Feldman T.E.
        • Ståhle E.
        • Colombo A.
        • Mack M.J.
        • Holmes Jr., D.R.
        • Morel M.A.
        • Van Dyck N.
        • Houle V.M.
        • Dawkins K.D.
        • Serruys P.W.
        Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.
        Lancet. 2013; 381: 629-638
        • Farkouh M.E.
        • Domanski M.
        • Sleeper L.A.
        • Siami F.S.
        • Dangas G.
        • Mack M.
        • Yang M.
        • Cohen D.J.
        • Rosenberg Y.
        • Solomon S.D.
        • Desai A.S.
        • Gersh B.J.
        • Magnuson E.A.
        • Lansky A.
        • Boineau R.
        • Weinberger J.
        • Ramanathan K.
        • Sousa J.E.
        • Rankin J.
        • Bhargava B.
        • Buse J.
        • Hueb W.
        • Smith C.R.
        • Muratov V.
        • Bansilal S.
        • King 3rd, S.
        • Bertrand M.
        • Fuster V.
        Strategies for multivessel revascularization in patients with diabetes.
        N Engl J Med. 2012; 367: 2375-2384
        • Flather M.
        • Wha Rhee J.
        • Boothroyd D.
        • Boersma E.
        • Mori Brooks M.
        • Carrié D.
        • Clayton T.
        • Danchin N.
        • Hamm C.
        • Hueb W.
        • King S.B.
        • Pocock S.P.
        • Rodriguez A.E.
        • Serruys P.W.
        • Sigwart U.
        • Stables R.
        • Hlatky M.A.
        The effect of age on outcomes of coronary artery bypass surgery compared with balloon angioplasty or bare-metal stent implantation among patients with multivessel coronary disease. A collaborative analysis of individual patient data from 10 randomized trials.
        J Am Coll Cardiol. 2012; 60: 2150-2157
        • Groeneveld P.W.
        • Matta M.A.
        • Greenhut A.P.
        • Yang F.
        Drug-eluting compared with bare-metal coronary stents among elderly.
        J Am Coll Cardiol. 2008; 51: 2017-2024
        • Rodriguez A.E.
        • Alemparte M.R.
        • Vigo C.F.
        • Pereira C.F.
        • Llaurado C.
        • Russo M.
        • Virmani R.
        • Ambrose J.A.
        Pilot study of oral rapamycin to prevent restenosis in patients undergoing Coronary stent therapy: Argentina Single-Center Study (ORAR Trial).
        J Invasive Cardiol. 2003; 15: 581-584
        • Waksman R.
        • Ajani A.E.
        • Pichard A.D.
        • Torguson R.
        • Pinnow E.
        • Canos D.
        • Satler L.F.
        • Kent K.M.
        • Kuchulakanti P.
        • Pappas C.
        • Gambone L.
        • Weissman N.
        • Abbott M.C.
        • Lindsay J.
        Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
        J Am Coll Cardiol. 2004; 44: 1386-1392
        • Rodriguez A.E.
        • Granada J.F.
        • Rodriguez-Alemparte M.
        • Vigo C.F.
        • Delgado J.
        • Fernandez- Pereira C.
        • Pocovi A.
        • Rodriguez-Granillo A.M.
        • Schulz D.
        • Raizner A.E.
        • Palacios I.
        • O'Neill W.
        • Kaluza G.L.
        • Stone G.
        Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
        J Am Coll Cardiol. 2006; 47: 1522-1529
        • Hausleiter J.
        • Kastrati A.
        • Mehilli J.
        • Vogeser M.
        • Zohlnhöfer D.
        • Schühlen H.
        • Goos C.
        • Pache J.
        • Dotzer F.
        • Pogatsa Murray G.
        • Dirschinger J.
        • Heemann U.
        • Schömig A.
        Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
        Circulation. 2004; 110: 790-795
        • Stojkovic S.
        • Ostojic M.
        • Nedeljkovic M.
        • Stankovic G.
        • Beleslin B.
        • Vukcevic V.
        • Orlic D.
        • Arandjelovic A.
        • Kostic J.
        • Dikic M.
        • Tomasevic M.
        Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation.
        Catheter Cardiovasc Interv. 2010; 75: 317-325
        • Versaci F.
        • Gaspardone A.
        • Tomai F.
        • Ribichini F.
        • Russo P.
        • Proietti I.
        • Ghini A.S.
        • Ferrero V.
        • Chiariello L.
        • Gioffre` P.A.
        • Romeo F.
        • Crea F.
        Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study).
        J Am Coll Cardiol. 2002; 40: 1935-1942
        • Ribichini F.
        • Tomai F.
        • Pesarini G.
        • Zivelonghi C,Rognoni A.
        • De Luca G.
        • Boccuzzi G.
        • Presbitero P.
        • Ferrero V.
        • Ghini A.
        • Marino P.
        • Vassanelli C.
        Long-term clinical follow-up of the multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA DES).
        Eur Heart J. 2013 Jun; 34: 1740-1748
        • Cernigliaro C.
        • Sansa M.
        • Vitrella G.
        • Verde A.
        • Bongo A.S.
        • Giuliani L.
        • Novelli E.
        Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up.
        Cardiology. 2010; 115: 77-86
        • Deftereos S.
        • Giannopoulos G.
        • Raisakis K.
        • Kossyvakis C.
        • Kaoukis A.
        • Panagopoulou V.
        • Driva M.
        • Hahalis G.
        • Pyrgakis V.
        • Alexopoulos D.
        • Manolis A.S.
        • Stefanadis C.
        • Cleman M.W.
        Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients.
        J Am Coll Cardiol. 2013; 61: 1679-1685
        • Claessen B.E.
        • Stone G.W.
        • Smits P.C.
        • Kedhi E.
        • Kikkert W.J.
        • Piek J.J.
        • Henriques J.P.
        Would SYNTAX have been a positive trial if XIENCE V have been used instead TAXUS? A meta-analysis of a first-generation vs a second generation drug-eluting system.
        Neth Heart J. 2010; 18: 451-453
        • Bischof M.
        • Briel M.
        • Bucher A.
        • Nordmann A.
        Cost effectiveness of DES in US Medicare system: a cost utility analysis of 3 years clinical follow up data.
        Value. Health. 2009; 12: 649-656